Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: A meta-analysis of randomized controlled trials
Autoři:
Mingyang Yu aff001; Rongguang Zhang aff001; Peng Ni aff001; Shuaiyin Chen aff001; Guangcai Duan aff001
Působiště autorů:
Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China
aff001
Vyšlo v časopise:
PLoS ONE 14(10)
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pone.0223309
Souhrn
Aim
To assess the effect of Lactobacillus supplementation on Helicobacter pylori eradication rates and side effects of the triple therapy.
Methods
PubMed, Embase, Web of Science and Cochrane Library were searched for articles published up to July, 2019. Review Manager 5.3 and Stata 12.0 were used for statistical analyses.
Results
The initial database search resulted in 852 articles. Through exclusion and screening, 11 randomized controlled trials involving a total of 724 patients were finally included in this meta-analysis. The H. pylori elimination rate in the Lactobacillus supplement group was significantly higher than that in the control group (RR 1.16, 95% CI 1.08–1.25, P<0.0001). Subgroup analysis showed that the eradication rates were significantly enhanced in both adults and children group, and no significant difference was detected between Asia and Europe group. In addition, sub-analysis based on duration of Lactobacillus supplementation showed the pooled RRs in the long-term and short-term groups were 1.17 (95%CI 1.06–1.30) and 1.16 (95% CI 1.04–1.30), respectively. Regarding the Lactobacillus strains, the pooled RR was 1.33 (95% CI 1.10–1.62) in the L. casei group, 1.18 (95% CI 1.03–1.34) in the L. reuteri group while 1.02 (95% CI 0.87–1.21) in the Lactobacillus GG group. As for the total side effects, Lactobacillus supplementation significantly reduced the incidence of taste disturbance (RR = 0.36, 95% CI 0.17–0.74, P = 0.005).
Conclusions
Lactobacillus supplementation during the treatment of Helicobacter pylori infection can effectively improve the eradication rates, and reduce the incidence of therapy-related taste disturbance.
Klíčová slova:
Helicobacter pylori – Antibiotics – Database searching – Lactobacillus – Histology – Gastrointestinal infections – Probiotics
Zdroje
1. Chen C, Mao Y, Du J, Xu Y, Zhu Z, Cao H. Helicobacter pylori infection associated with an increased risk of colorectal adenomatous polyps in the Chinese population. BMC Gastroenterol. 2019; 19 (1): 14. doi: 10.1186/s12876-018-0918-4 30665367
2. Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014; 345 (2): 196–202. doi: 10.1016/j.canlet.2013.08.016 23981572
3. Jarosz M, Rychlik E, Siuba M, Respondek W, Ryzko-Skiba M, Sajór I, et al. Dietary and socio-economic factors in relation to Helicobacter pylori re-infection. World J Gastroenterol. 2009; 15 (9): 1119–25. doi: 10.3748/wjg.15.1119 19266606
4. Fallone CA, Chiba N, Fischbach L, Zanten SV, Gisbert JP, Hunt RH, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016; 151 (1): 51–69. doi: 10.1053/j.gastro.2016.04.006 27102658
5. Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol. 2014; 20 (18): 5283–93. doi: 10.3748/wjg.v20.i18.5283 24833858
6. Vitor JMB, Vale FF. Alternative therapies for Helicobacter pylori:probiotics and phytomedicine. FEMS Immunol Med Microbiol. 2011; 63: 153–64. doi: 10.1111/j.1574-695X.2011.00865.x 22077218
7. García A, Sáez K, Delgado C, González CL. Low co-existence rates of Lactobacillus spp, and Helicobacter pylori detected in gastric biopsies from patients with gastrointestinal symptoms. Rev Esp Enferm Dig. 2012;104:473–8. doi: 10.4321/s1130-01082012000900005 23130855
8. Mégraud F. Antibiotic resistance is the key element in treatment of Helicobacter pylori infection. Gastroenterology. 2018; 155 (5): 1300–2. doi: 10.1053/j.gastro.2018.10.012 30308190
9. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59 (8): 1143–53. doi: 10.1136/gut.2009.192757 20525969
10. Parker EA, Roy T, D'Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition. 2018; 45: 125–34. doi: 10.1016/j.nut.2017.06.024 28870406
11. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther. 2006; 23 (8): 1077–86. doi: 10.1111/j.1365-2036.2006.02868.x 16611267
12. Wang YH, Huang Y. Effect of Lactobacillus acidophilus and Bifidobacterium bifidum supplementation to standard triple therapy on Helicobacter pylori eradication and dynamic changes in intestinal flora. World J Microbiol Biotechnol. 2014; 30:847–53. doi: 10.1007/s11274-013-1490-2 24233772
13. Shavakhi A, Ahmad S, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, et al. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. Helicobacter. 2013; 18:280–84. doi: 10.1111/hel.12047 23433200
14. Szajewska H. Pooling data on different probiotics is not appropriate to assess the efficacy of probiotics. Eur J Pediatr. 2014; 173 (7): 975. doi: 10.1007/s00431-014-2340-4 24849615
15. Sgouras D, Maragkoudakis P, Petraki K, Eriotou E, Michopoulos S, Kalantzopoulos G, et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol. 2004; 70 (1): 518–26. doi: 10.1128/AEM.70.1.518-526.2004 14711683
16. Yang YJ, Chuang CC, Yang HB, Lu CC, Sheu BS. Lactobacillus acidophilus ameliorates H. pylori-induced gastric inflammation by inactivating the Smad7 and NFkappaB pathways. BMC Microbiol. 2012; 12: 38. doi: 10.1186/1471-2180-12-38 22429929
17. Lorca GL, Wadström T, Valdez GF, Ljungh A. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol. 2001; 42 (1): 39–44. 11116395
18. Isobe H, Nishiyama A, Takano T, Higuchi W, Nakagawa S, Taneike I, et al. Reduction of overall Helicobacter pylori colonization levels in the stomach of Mongolian gerbil by Lactobacillus johnsonii La1 (LC1) and its in vitro activities against H. pylori motility and adherence. Biosci Biotechnol Biochem. 2012; 76 (4): 850–52. doi: 10.1271/bbb.110921 22484956
19. Cui Y, Wang CL, Liu XW, Wang XH, Chen LL, Zhao X et al. Two stomach-originated Lactobacillus strains improve Helicobacter pylori infected murine gastritis. World J Gastroenterol. 2010; 16 (4): 445–52. doi: 10.3748/wjg.v16.i4.445 20101769
20. Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine. 2019; 98(15): e15180. doi: 10.1097/MD.0000000000015180 30985706
21. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011.
22. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009; 62 (10): 1–34. doi: 10.1016/j.jclinepi.2009.06.006 19631507
23. Schunemann H, Brozek J, Guyatt G. GRADE handbook for grading quality of evidence and strength of recommendations (updated October 2013). The GRADE Working Group. 2013.
24. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analysis. BMJ. 2003; 327: 557–60. doi: 10.1136/bmj.327.7414.557 12958120
25. DerSimonian R, Laird N. Meta-analysis in clinical trails. Control Clin Trails. 1986; 7: 177–88. 3802833
26. Deguchi R, Nakaminami H, Rimbara E, Noguchi N, Sasatsu M, Suzuki T, et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. J Gastroen Hepatol. 2011; 27 (5): 888–92. doi: 10.1111/j.1440-1746.2011.06985.x 22098133
27. Sýkora J, Valecková K, Amlerová J, Siala K, Dedek P, Watkins S, et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: A prospective randomized double-blind study. J Clin Gastroenterol. 2005; 39 (8): 692–98. doi: 10.1097/01.mcg.0000173855.77191.44 16082279
28. José E, Sahagún F, Mónica S, et al. Erradicación de Helicobacter pylori: esquema triple tradicional versus mismo esquema más probiótico. Cirugía y Cirujanos. 2007; 75 (5): 333–6. 18158878
29. Medeiros JA, Gonçalves TM, Boyanova L, Pereira MI, Pereira AM, Cabrita AM, et al. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol. 2011; 30 (4): 555–59. doi: 10.1007/s10096-010-1119-4 21207091
30. Ojetti V, Bruno G, Ainora ME, Gigante G, Rizzo G, Roccarina D, et al. Impact of Lactobacillus reuteri Supplementation on anti-Helicobacter pylori levofloxacin-based second-line therapy. Gastroent Res Pract. 2012; 2012: 1–6. doi: 10.1155/2012/740381 22690211
31. Emara MH, Mohamed SY, Abdel-Aziz HR. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Ther Advin Gastroenter. 2014; 7 (1): 4–13. doi: 10.1177/1756283X13503514 24381643
32. Shahraki T, Shahraki M, Shahri E, et al. No significant impact of Lactobacillus reuteri on eradication of Helicobacter pylori in children (double-blind randomized clinical trial). IRAN Red Crescent. 2017; 19: 421. doi: 10.5812/ircmj.42101
33. Szajewska H, Albrecht Y, Topczewska-Cabanek Z. Randomized, double-blind, placebo-controlled trial: effect of Lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastr Nutr. 2009; 48 (4): 431–6. doi: 10.1097/mpg.0b013e318182e716 19330931
34. Francavilla R, Polimeno L, Demichina A, Maurogiovanni G, Principi B, Scaccianoce G, et al. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J Clin Gastroenterol. 2014; 48 (5):407–13. doi: 10.1097/MCG.0000000000000007 24296423
35. Armuzzi A, Cremonini F, Ojetti V, Bartolozzi F, Canducci F, Candelli M, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion. 2001; 63 (1):1–7. doi: 10.1159/000051865 11173893
36. Lionetti E, Miniello VL, Castellaneta SP, Magistá AM, Canio A, Maurogiovanni G, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther. 2006; 15 24 (10): 1461–8. doi: 10.1111/j.1365-2036.2006.03145.x 17032283
37. Coconnier MH, Lievin V, Hemery E, Servin AL. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol. 1998; 64 (11): 4573–80. 9797324
38. Sung M, Lim. Anti-Helicobacter pylori activity of antimicrobial substances produced by lactic acid bacteria isolated from Baikkimchi. Applied Biological Chemistry. 2014; 57 (5): 621–30. doi: 10.1007/s13765-014-4198-6
39. Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N, et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter. 2008; 13 (2): 127–34. doi: 10.1111/j.1523-5378.2008.00593.x 18321302
40. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002; 32 (2): 105–10. doi: 10.1111/j.1574-695X.2002.tb00541.x 11821231
41. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003; 52 (6): 827–33. doi: 10.1136/gut.52.6.827 12740338
42. Myllyluoma E, Ahonen AM, Korpela R, Vapaatalo H, Kankuri E. Effects of multispecies probiotic combination on Helicobacter pylori infection in vitro. Clin Vaccine Immunol. 2008; 15 (9): 1472–82. doi: 10.1128/CVI.00080-08 18579692
43. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007; 13 (1): 35–7. doi: 10.1038/nm1521 17159985
44. Zheng X, Yu L, Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 2013; 105 (8): 445–53. doi: 10.4321/s1130-01082013000800002 24274441
45. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013; 47 (1): 25–32. doi: 10.1097/MCG.0b013e318266f6cf 23090045
46. Fang HR, Zhang GQ, Cheng JY, Li ZY. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr. 2019; 178 (1): 7–16. doi: 10.1007/s00431-018-3282-z 30446816
47. Feng JR, Wang F, Qiu X, McFarland LV, Chen PF, Zhou R, et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2017; 73(10):1199–208. doi: 10.1007/s00228-017-2291-6 28681177
48. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007; 12 (4):309–16. doi: 10.1111/j.1523-5378.2007.00516.x 17669103
49. Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr. 2009; 98(1):127–31. doi: 10.1111/j.1651-2227.2008.00977.x 18681892
50. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002; 97(11):2744–9. doi: 10.1111/j.1572-0241.2002.07063.x 12425542
51. Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med. 2015; 9 (3):707–16. doi: 10.3892/etm.2015.2174 25667617
52. Li S, Huang XL, Sui JZ, Chen SY, Xie YT, Deng Y, et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr. 2014; 173 (2):153–61. doi: 10.1007/s00431-013-2220-3 24323343
Článok vyšiel v časopise
PLOS One
2019 Číslo 10
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Eliquis (apixaban) nově hrazen ze zdravotního pojištění
Najčítanejšie v tomto čísle
- Correction: Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study
- Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
- Risk factors associated with IgA vasculitis with nephritis (Henoch–Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis
- Prevalence of pectus excavatum (PE), pectus carinatum (PC), tracheal hypoplasia, thoracic spine deformities and lateral heart displacement in thoracic radiographs of screw-tailed brachycephalic dogs